St. Clair Advisors LLC Invests $3.11 Million in Johnson & Johnson (NYSE:JNJ)

St. Clair Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,470 shares of the company's stock, valued at approximately $3,105,000. Johnson & Johnson accounts for 0.9% of St. Clair Advisors LLC's holdings, making the stock its 24th biggest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $32,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $36,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on JNJ shares. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America reduced their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Stock Up 1.2%

Johnson & Johnson stock opened at $151.37 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $364.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business has a fifty day moving average price of $156.27 and a 200-day moving average price of $153.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.44%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is presently 57.84%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.